NewsHKSubscribe
Markets市場

SERB Pharmaceuticals Acquires European and MENA Rights to Idefirix® from Hansa Biopharma in €115 Million Deal

SERB Pharmaceuticals has agreed to acquire exclusive development and commercialization rights to Idefirix® (Imlifidase) from Swedish biotech Hansa Biopharma AB (Nasdaq Stockholm: HNSA) for €115 million, the companies announced in…

By Mara Whitfield·June 23, 2026·二〇二六年六月二十三日·2 min read

Source · 來源

globenewswire.com

Share · 分享
Xinfw
← Back to the News DeskFiled · Markets

Related Dispatches

相關報導
News Desk →
  1. 01Markets市場

    Eli Lilly earnings set to test obesity drug momentum

    The obesity drug market has drawn sustained investor attention across the pharmaceutical sector, and Eli Lilly and Company…

    August 4, 2026 · 2 min

  2. 02Markets市場

    AMD options market prices in 8.5% earnings swing ahead of Q2 print

    Options markets tend to concentrate risk around earnings dates, and positioning in semiconductor names has sharpened going into…

    August 3, 2026 · 2 min

  3. 03Markets市場

    Goldman Sachs partner sees S&P 500 extending all-time highs through year-end

    Against a backdrop of shifting rate expectations and cross-border capital repositioning, equity sentiment on Wall Street is…

    August 3, 2026 · 2 min

Elsewhere on the Desk

All Dispatches →
Earnings

SoftBank profit beats expectations on $8.2 billion Intel investment gain

August 6, 2026 · 2 min

Earnings

AMD sinks 7% despite earnings beat as AI chip rally tests its ceiling

August 6, 2026 · 2 min

Macro

China tax crackdown fears pull insurance and bank stocks lower

August 6, 2026 · 2 min

Earnings

AMD shares slip after earnings as Su dismisses Musk's Nvidia commitment

August 6, 2026 · 2 min